Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.
There are some skin conditions we're very familiar with: spots during adolescence, allergic rashes, sunburn. But others are ...
MacTel is a rare, progressive eye disease that affects the macula and causes a gradual deterioration in central vision.
The US Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular ...
Neurotech Pharma's cell therapy Encelto has become the first FDA-approved treatment for idiopathic macular telangiectasia ...
Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...
Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and Drug Administration (FDA), has ...
About Macular Telangiectasia Type 2 (MacTel) Macular Telangiectasia Type 2 (MacTel), or idiopathic macular telangiectasia type 2, is a bilateral, neurodegenerative disease in adults with ...
MedPage Today on MSN11d
FDA Approves Ocular Implant for Vision-Threatening MacTelThe FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia ...
Revakinagene taroretcel-lwey (Encelto; Neurotech), an allogeneic encapsulated cell-based gene therapy, is the first therapy to be approved for macular telangiectasia type 2. The FDA approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback